2021
HIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death
Freiberg MS, Duncan MS, Alcorn C, Chang C, Kundu S, Mumpuni A, Smith EK, Loch S, Bedigian A, Vittinghoff E, So‐Armah K, Hsue PY, Justice AC, Tseng ZH. HIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death. Journal Of The American Heart Association 2021, 10: e021268. PMID: 34493058, PMCID: PMC8649505, DOI: 10.1161/jaha.121.021268.Peer-Reviewed Original ResearchConceptsHIV viral loadCD4 cell countFirst clinical visitHIV infectionViral loadSCD riskCell countWorld Health OrganizationCopies/Elevated HIV viral loadLow CD4 cell countsSudden cardiac death rateVeterans Aging Cohort StudyCox proportional hazards regressionHealth OrganizationConclusions HIV infectionSCD risk factorsCardiac death rateAging Cohort StudyProportional hazards regressionSudden cardiac deathCells/Mean baseline ageRace/ethnicityCohort study
2019
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systems
2018
Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l
Kong CY, Sigel K, Criss SD, Sheehan DF, Triplette M, Silverberg MJ, Henschke CI, Justice A, Braithwaite RS, Wisnivesky J, Crothers K. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l. AIDS 2018, 32: 1333-1342. PMID: 29683843, PMCID: PMC5991188, DOI: 10.1097/qad.0000000000001818.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer screeningCD4 cell countMedicaid Services criteriaCancer screeningLung cancerMortality reductionCell countLDCT examinationsAnnual low-dose computed tomographyUninfected individualsLung cancer mortality reductionVeterans Aging Cohort StudyCancer mortality reductionAntiretroviral therapy adherenceAging Cohort StudyLung cancer mortalityCells/Lung Cancer Policy ModelMultiple national organizationsAlternative screening strategiesBase-case analysisHIV cohortCohort studyFormer smokersAssociation of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease
Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz M, Tindle HA, Sico J, Tracy RP, Justice AC, Freiberg MS. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation 2018, 138: 255-265. PMID: 29535090, PMCID: PMC6050082, DOI: 10.1161/circulationaha.117.032647.Peer-Reviewed Original ResearchConceptsRisk of PADIncident PAD eventsPeripheral artery diseaseHuman immunodeficiency virusCD4 cell countTraditional atherosclerotic risk factorsPAD risk factorsAtherosclerotic risk factorsPAD eventsRisk factorsCell countUninfected veteransCD4 cellsArtery diseaseHIV infectionHIV statusViral loadCells/Peripheral artery disease eventsPrior peripheral artery diseaseHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyHIV-1 ribonucleic acidHIV infection statusHIV viral load
2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeterans
2013
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, Research and Design of IeDEA F. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLOS ONE 2013, 8: e81355. PMID: 24367482, PMCID: PMC3867319, DOI: 10.1371/journal.pone.0081355.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive adultsMortality rateLife expectancyNorth American AIDS Cohort CollaborationHIV transmission risk groupTransmission risk groupsCombination antiretroviral therapyInjection drug useHIV-positive individualsCrude mortality rateComparable life expectancyBaseline CD4Cohort CollaborationART initiationCD4 countAge-specific mortality ratesRisk groupsPositive adultsGeneral populationDrug useAge 20Cells/AdultsAdditional year
2010
Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD, Research and Design N. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases 2010, 50: 1512-1520. PMID: 20415573, PMCID: PMC2862849, DOI: 10.1086/652650.Peer-Reviewed Original ResearchConceptsMean CD4 countPercentage of patientsHIV transmission riskCD4 countHIV careFirst presentationTransmission riskCells/North American AIDS Cohort CollaborationHuman immunodeficiency virus (HIV) careHuman immunodeficiency virus (HIV) servicesHeterosexual transmission riskMedian CD4 countEarly HIV diagnosisT-lymphocyte countsHIV RNA measurementsHistory of AIDSRace/ethnicityAntiretroviral exposureCohort CollaborationHIV diagnosisLymphocyte countInitial presentationMedian ageLate presentation
2007
Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity?
Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC. Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? Clinical Infectious Diseases 2007, 45: 1593-1601. PMID: 18190322, PMCID: PMC3687553, DOI: 10.1086/523577.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCD4 cell countPatterns of comorbidityHIV infectionHIV statusCell countHIV severityOlder human immunodeficiency virusPrimary care guidelinesClinical Modification codesCells/Pulmonary diseaseComorbid conditionsMultivariable analysisViral loadCare guidelinesImmunodeficiency virusComorbiditiesInternational ClassificationMultimorbidityInfectionPresence of conditionsVeteransAgeDiseaseDelayed Presentation for Human Immunodeficiency Virus (HIV) Care Among Veterans
Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. Delayed Presentation for Human Immunodeficiency Virus (HIV) Care Among Veterans. Medical Care 2007, 45: 1105-1109. PMID: 18049352, PMCID: PMC3460382, DOI: 10.1097/mlr.0b013e3181271476.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVeterans Health AdministrationHIV presentationHIV careClinical triggersVA healthcareHuman immunodeficiency virus (HIV) careImmune deficiency syndrome diagnosisHIV-positive patientsHalf of patientsRetrospective observational studyCells/Immune deficiency syndromeHalf of veteransVA Medical CenterYear of presentationAntiretroviral therapyCD4 countHIV screeningMedian durationHIV infectionPhysician visitsImmunodeficiency virusDeficiency syndromeObservational studyPrognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefit